All In Biotech

Drug Trial Radar · NCT03806309

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Apr 10, 2021

Primary completion

Dec 9, 2024

Study completion Dec 2025

Sponsor

Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
OSE Immunotherapeutics
First posted
Jan 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Locally Advanced Cancer
  • Metastatic Cancer

Interventions

  • FOLFIRIDrug

    Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2

  • OSE2101Drug

    subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: At 12 months

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Clinique de l'Europe

    Amiens, France

  • Hôpital Sud CHU Amiens

    Amiens, France

  • CH Beauvais

    Beauvais, France

  • CHRU Jean Minjoz

    Besançon, France

  • Clinique Tivoli Ducos

    Bordeaux, France

  • CHU Morvan

    Brest, France

  • GHPSO Site de Creil

    Creil, France

  • Hôpital Henri Mondor

    Créteil, France

  • Centre Georges François Leclerc

    Dijon, France

  • CHU Dijon

    Dijon, France

  • CHRU Lille

    Lille, France

  • centre Léon Bérard

    Lyon, France

  • Hôpital Edouard Herriot

    Lyon, France

  • Hôpital la Croix Rousse

    Lyon, France

  • Hôpital Lyon Sud Hospices Civils de Lyon

    Lyon, France

  • Hôpital Privé Jean Mermoz

    Lyon, France

  • Hôpital Européen

    Marseille, France

  • Institut Paoli Calmette

    Marseille, France

  • Hôpital Pitié Salpêtrière

    Paris, France

  • Hôpital Saint Antoine

    Paris, France

  • Institut Mutualiste Montsouris

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • CHU Robert Debré

    Reims, France

  • Institut Curie

    Saint-Cloud, France

  • Centre Paul Strauss

    Strasbourg, France

  • Clinique Pasteur

    Toulouse, France

  • Hôpital TROUSSEAU

    Tours, France

  • Insitut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.